ArticleClinical rheumatology2024
Burden evaluation and prediction of osteoarthritis and site-specific osteoarthritis coupled with attributable risk factors in China from 1990 to 2030.
Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- From regeneration to immunomodulation: a 20-year global bibliometric analysis of platelet-rich plasma for osteoarthritis.Frontiers in medicine · 2026Pooled it
- Efficacy and safety of single versus repeated injections of mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.Stem cell research & therapy · 2025Pooled it
- Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis.Bioactive materials · 2026Article
- Global, regional, and national burden of knee osteoarthritis: findings from the Global Burden of Disease study 2021 and projections to 2045.Journal of orthopaedic surgery and research · 2025Article
- Intelligent Manufacturing for Osteoarthritis Organoids.Cell proliferation · 2025Review
- Identification and validation of hub m7G-related genes and infiltrating immune cells in osteoarthritis based on integrated computational and bioinformatics analysis.BMC musculoskeletal disorders · 2025Article
- The global burden of osteoarthritis knee: a secondary data analysis of a population-based study.Clinical rheumatology · 2025Article
- Burden of osteoarthritis in older adults (aged ≥55 years) in the United States and China: a comparative analysis of temporal trends, risk factor contributions, and projected burden to 2030 using global burden of disease study 2021 data.Frontiers in medicine · 2025Article
- Association between BMI and knee osteoarthritis in Chinese adults aged 45 years and older: evidence from the 2021 Global Burden of Disease analysis and the China Health and Retirement Longitudinal Study.Frontiers in public health · 2025Article
- Global, region and country burden of osteoarthritis at different sites in middle-aged and elderly populations from 1990 to 2021: a systematic analysis of the 2021 global burden of disease study.Frontiers in medicine · 2025Article
- The association of antihistamines and new-onset osteoarthritis in patients with autoimmune disease: a population-based cohort study.Frontiers in immunology · 2025Article
- Study of adiponectin gene (rs1501299) polymorphism and serum adiponectin level in patients with primary knee osteoarthritis.Human genomics · 2024Article
- Kinematic effects of unilateral TKA on the contralateral knee in Chinese patients with advanced osteoarthritis: a prospective gait analysis study.Frontiers in bioengineering and biotechnology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveThis study aimed to estimate and predict the burden of osteoarthritis (OA) and site-specific OA (hip, knee, hand, and others) from 1990 to 2030 and their attributable risk factors in China.
methodData were obtained from the Global Burden of Diseases 2019. The burden was estimated by analyzing the trends of prevalence, incidence, and disability-adjusted life years (DALY). Population attributable risk (PAR) was calculated to assess the impact of high body mass index (BMI). The prediction from 2020 to 2030 was implemented by Bayesian age-period-cohort analysis.
resultsIn China, prevalent cases, DALY, and incident cases of OA increased to 132.81 million, 4.72 million, and 10.68 million, respectively. Age-standardized rates (ASRs) of prevalence, DALYs, and incidence increased for OA and site-specific OA, especially for hip OA. Site-specific OA showed different susceptible peaking ages, and the burden for those over 50 years old became serious. Female preference existed in the trends for knee OA but not in those for hip, hand, and other OA. PARs of high BMI continued to increase, impacting knee OA more than hip OA and showing female preference. In the next decade, incident cases for OA and site-specific OA will continue to increase, despite that the ASR of OA incidence will decrease.
conclusionsOA and site-specific OA remain huge public health challenges in China. The burden of OA and site-specific OA is increasing, especially among people over 50 years old. Health education, exercise, and removing modifiable risk factors contribute to alleviate the growing burden. Key Points • In China, the burden of osteoarthritis and site-specific osteoarthritis (hip, knee, hand, and others) as well as the Risk Factor (high body mass index) increased greatly from 1990 to 2019. • It is estimated that incident cases for OA and site-specific OA will continue to increase, despite that the ASR of OA incidence will decrease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.